Virginia · A9607

Lutetium Lu 177 Vipivotide Tetraxetan, Therapeutic, 1 Millicurie in Virginia

Virginia Medicare Avg
$225.78
14% above national avg
National Medicare Avg
$197.94
All states combined
Billed Charge (VA)
$567.19
What providers submit
Est. Commercial (VA)
$623.45
National avg: $556.53
Est. Cash / Self-Pay (VA)
$368.52
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

31.5K
Services in VA
8
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Virginia

Provider Medicare Services
Archie, Victor MD $255.29 10.2K
Agbahiwe, Harold M.D. $197.11 8.4K
Sibley, Gregory M.D. $204.23 8.2K

Virginia Pricing in Context

In Virginia, CPT code A9607 (Lutetium Lu 177 Vipivotide Tetraxetan, Therapeutic, 1 Millicurie) carries an average Medicare payment of $225.78 — 14% above the national benchmark of $197.94. 8 providers across the state submitted claims for this procedure in 2023, performing 31.5K total services. Individual payments in VA ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Virginia is $567.19, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Virginia sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Medical Supplies procedures, the estimated commercial insurance price in Virginia lands near $623.45, with self-pay cash prices typically around $368.52. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Lutetium Lu 177 Vipivotide Tetraxetan, Therapeutic, 1 Millicurie cost in Virginia?

The average Medicare payment for Lutetium Lu 177 Vipivotide Tetraxetan, Therapeutic, 1 Millicurie in Virginia is $225.78, which is 14% above the national average of $197.94. Providers in VA typically bill $567.19 for this procedure.

What does Lutetium Lu 177 Vipivotide Tetraxetan, Therapeutic, 1 Millicurie cost with insurance in Virginia?

With commercial insurance in Virginia, Lutetium Lu 177 Vipivotide Tetraxetan, Therapeutic, 1 Millicurie costs an estimated $623.45. Without insurance, the estimated cash price is $368.52. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Lutetium Lu 177 Vipivotide Tetraxetan, Therapeutic, 1 Millicurie in Virginia?

8 providers in Virginia billed Medicare for Lutetium Lu 177 Vipivotide Tetraxetan, Therapeutic, 1 Millicurie in 2023, performing 31.5K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Lutetium Lu 177 Vipivotide Tetraxetan, Therapeutic, 1 Millicurie cheaper in Virginia than the national average?

No — Lutetium Lu 177 Vipivotide Tetraxetan, Therapeutic, 1 Millicurie costs 14% above the national average in Virginia. The state average Medicare payment is $225.78 compared to $197.94 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial